Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 23:3:69.
doi: 10.3389/fmed.2016.00069. eCollection 2016.

Liquid Biopsy in Non-Small Cell Lung Cancer

Miguel A Molina-Vila  1 , Clara Mayo-de-Las-Casas  1 , Ana Giménez-Capitán  1 , Núria Jordana-Ariza  1 , Mónica Garzón  1 , Ariadna Balada  1 , Sergi Villatoro  1 , Cristina Teixidó  1 , Beatriz García-Peláez  1 , Cristina Aguado  1 , María José Catalán  1 , Raquel Campos  1 , Ana Pérez-Rosado  1 , Jordi Bertran-Alamillo  1 , Alejandro Martínez-Bueno  2 , María-de-Los-Llanos Gil  2 , María González-Cao  2 , Xavier González  2 , Daniela Morales-Espinosa  2 , Santiago Viteri  2 , Niki Karachaliou  2 , Rafael Rosell  3
Affiliations
Review

Liquid Biopsy in Non-Small Cell Lung Cancer

Miguel A Molina-Vila et al. Front Med (Lausanne). .

Abstract

Liquid biopsy analyses are already incorporated in the routine clinical practice in many hospitals and oncology departments worldwide, improving the selection of treatments and monitoring of lung cancer patients. Although they have not yet reached its full potential, liquid biopsy-based tests will soon be as widespread as "standard" biopsies and imaging techniques, offering invaluable diagnostic, prognostic, and predictive information. This review summarizes the techniques available for the isolation and analysis of circulating free DNA and RNA, exosomes, tumor-educated platelets, and circulating tumor cells from the blood of cancer patients, presents the methodological challenges associated with each of these materials, and discusses the clinical applications of liquid biopsy testing in lung cancer.

Keywords: CTCs; ctDNA; ctRNA; exosomes; gene fusions; lung cancer; mutations; tumor-educated platelets.

PubMed Disclaimer

References

    1. Kidess E, Jeffrey SS. Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis? Genome Med (2013) 5:70.10.1186/gm474 - DOI - PMC - PubMed
    1. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med (2008) 14:985–90.10.1038/nm.1789 - DOI - PMC - PubMed
    1. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov (2014) 4:650–61.10.1158/2159-8290.CD-13-1014 - DOI - PMC - PubMed
    1. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res (2001) 61:4675–8. - PubMed
    1. Sirera R, Bremnes RM, Cabrera A, Jantus-Lewintre E, Sanmartín E, Blasco A, et al. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol (2011) 6:286–90.10.1097/JTO.0b013e31820189a5 - DOI - PubMed

LinkOut - more resources